Advertisement

Chagas Disease pp 299-312 | Cite as

Clinical Pharmacology of Drugs for the Treatment of Chagas Disease

  • Facundo Garcia-Bournissen
Chapter
Part of the Birkhäuser Advances in Infectious Diseases book series (BAID)

Abstract

Chagas disease is a parasitic disease endemic to Latin America that, if left untreated, can lead to severe long-term organ damage, particularly in the heart and gastrointestinal tract. Treatment with benznidazole or nifurtimox has been shown to be effective in the acute phase and during childhood, and limited evidence suggest a beneficial effect later in life too. However, both drugs require prolonged treatments (30–60 days) and are associated to significant adverse events that increase in severity and prevalence with age. Prompt pediatric diagnosis and treatment are vital for an effective use of these medications.

Keywords

Chagas disease Benznidazole Nifurtimox Clinical pharmacology Adverse events 

References

  1. 1.
    Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388–402. PubMed PMID: 20399979.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102(Suppl 1):75–85. PubMed PMID: 17891282.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. 2010;115(1–2):14–21. PubMed PMID: 19932071.PubMedCrossRefGoogle Scholar
  4. 4.
    Carlier Y. Globalization of Chagas disease (American trypanosomiasis): the situation in Europe and Belgium. Bull Mem l’Acad R Med Belg. 2011;166(10–12):347–55. discussion 56–7. PubMed PMID: 23082500.Google Scholar
  5. 5.
    Teixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA. Chagas disease. Postgrad Med J. 2006;82(974):788–98. Pubmed Central PMCID: 2653922.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Teixeira AR, Nascimento RJ, Sturm NR. Evolution and pathology in Chagas disease—a review. Mem Inst Oswaldo Cruz. 2006;101(5):463–91. PubMed PMID: 17072450.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther. 2010;4:243–53. PubMed PMID: 20957215. Pubmed Central PMCID: 2948934.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Stoppani AOM. Quimioterapia de la enfermedad de Chagas. Medicina (B Aires). 1999;59(Suppl 2):147–65.Google Scholar
  9. 9.
    Buckner FS, Bahia MT, Suryadevara PK, White KL, Shackleford DM, Chennamaneni NK, et al. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012;56(9):4914–21. PubMed PMID: 22777048. Pubmed Central PMCID: 3421879.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Chatelain E. Chagas disease drug discovery: toward a new era. J Biomol Screen. 2015;20(1):22–35. PubMed PMID: 25245987.PubMedCrossRefGoogle Scholar
  11. 11.
    Molina I, Gomez i, Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–908. PubMed PMID: 24827034.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Perez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. PubMed PMID: 28673423.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Sales Junior PA, Molina I, Fonseca Murta SM, Sanchez-Montalva A, Salvador F, Correa-Oliveira R, et al. Experimental and clinical treatment of Chagas disease: a review. Am J Trop Med Hyg. 2017;97(5):1289–303. PubMed PMID: 29016289.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Wilkinson SR, Bot C, Kelly JM, Hall BS. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem. 2011;11(16):2072–84. PubMed PMID: 21619510.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem. 2011;286(15):13088–95. Pubmed Central PMCID: 3075655.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A. 2008;105(13):5022–7. PubMed PMID: 18367671. Pubmed Central PMCID: 2278226.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Vazquez K, Paulino M, Salas CO, Zarate-Ramos JJ, Vera B, Rivera G. Trypanothione reductase: a target for the development of anti-Trypanosoma cruzi drugs. Mini Rev Med Chem. 2017;17(11):939–46. PubMed PMID: 28302040.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AO. The chemotherapy of Chagas’ disease: an overview. Mini Rev Med Chem. 2005;5(5):499–519. PubMed PMID: 15892691.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348(9039):1407–13. PubMed PMID: 8937280.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Viotti R, Alarcon de Noya B, Araujo-Jorge T, Grijalva MJ, Guhl F, Lopez MC, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635–9. PubMed PMID: 24247135. Pubmed Central PMCID: 3910900.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti-Infect Ther. 2009;7(2):157–63. PubMed PMID: 19254164.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hygiene. 1998;59(4):526–9. PubMed PMID: 9790423.CrossRefGoogle Scholar
  23. 23.
    Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics. 2011;127(1):e212–8. PubMed PMID: 21173000.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Marin-Neto JA, Rassi Júnior A, Mattos AC, Avezum Júnior A, Rassi A. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):319–24.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Fernández ML, Marson ME, Ramirez JC, Mastrantonio G, Schijman AG, Altcheh J, et al. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole. Mem Inst Oswaldo Cruz. 2016;111(3):218–21.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Garcia-Bournissen F, Moroni S, Marson ME, Moscatelli G, Mastrantonio G, Bisio M, et al. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. Arch Dis Child. 2015;100(1):90–4. PubMed PMID: 25210104.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis. 2014;8(5):e2907. PubMed PMID: 24853169. Pubmed Central PMCID: 4031103.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Garcia-Bournissen F, Altcheh J, Giglio N, Mastrantonio G, Della Vedova CO, Koren G. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina. Paediatr Drugs. 2009;11(1):33–7. PubMed PMID: 19127950.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz. 2007;102(Suppl 1):95–7. PubMed PMID: 17906803.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Pinheiro E, Brum-Soares L, Reis R, Cubides J-C. Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America. Rev Soc Bras Med Trop. 2017;50(3):296–300.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Alpern JD, Lopez-Velez R, Stauffer WM. Access to benznidazole for Chagas disease in the United States-cautious optimism? PLoS Negl Trop Dis. 2017;11(9):e0005794. PubMed PMID: 28910299. Pubmed Central PMCID: 5598921.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Richle RW, Raaflaub J. Difference of effective antitrypanosomal dosages of benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results. Acta Trop. 1980;37(3):257–61. PubMed PMID: 6106364.PubMedGoogle Scholar
  33. 33.
    Chatelain E, Ioset JR. Phenotypic screening approaches for Chagas disease drug discovery. Expert opinion on drug discovery. Expert Opin Drug Discov. 2018;13:141–53. PubMed PMID: 29235363.PubMedCrossRefGoogle Scholar
  34. 34.
    Romanha AJ, Castro SL, Soeiro MNC, Lannes-Vieira J, Ribeiro I, Talvani A, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother. 2012;56(1):115–23. PubMed PMID: 22037852. Pubmed Central PMCID: 3256028.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Roberts JT, Bleehen NM. Benznidazole with CCNU: a clinical phase I toxicity study. Int J Radiat Oncol Biol Phys. 1985;11(2):331–4. PubMed PMID: 3972652.PubMedCrossRefGoogle Scholar
  37. 37.
    Raaflaub J. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung. 1980;30(12):2192–4. PubMed PMID: 6783051.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Workman P, White RA, Walton MI, Owen LN, Twentyman PR. Preclinical pharmacokinetics of benznidazole. Br J Cancer. 1984;50(3):291–303. PubMed PMID: 6466543. Pubmed Central PMCID: 1976805.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Roberts JT, Bleehen NM, Lee FY, Workman P, Walton MI. A phase I study of the combination of benznidazole and CCNU in man. Int J Radiat Oncol Biol Phys. 1984;10(9):1745–8. PubMed PMID: 6480457.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Bisio M, Altcheh J, Lattner J, Moscatelli G, Fink V, Burgos JM, et al. Benznidazole treatment of chagasic encephalitis in pregnant woman with AIDS. Emerg Infect Dis. 2013;19(9):1490–2. PubMed PMID: 23965334. Pubmed Central PMCID: 3810932.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Walton MI, Workman P. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol. 1987;36(6):887–96. PubMed PMID: 3105539.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Workman P, Walton MI, Lee FY. Benznidazole: nitroreduction and inhibition of cytochrome P-450 in chemosensitization of tumour response to cytotoxic drugs. Biochem Pharmacol. 1986;35(1):117–9. PubMed PMID: 3940522.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA. [Longitudinal study and specific chemotherapy in children with chronic Chagas’ disease, residing in a low endemicity area of Argentina]. Estudo longitudinal e quimioterapia especifica em criancas, com doenca de Chagas cronica, residentes em area de baixa endemicidade da Republica Argentina. Rev Soc Bras Med Trop. 2004;37(5):365–75.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Alvarez MG, Vigliano C, Lococo B, Bertocchi G, Viotti R. Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study. Acta Trop. 2017;174:149–52. PubMed PMID: 28720492.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Bertocchi GL, Vigliano CA, Lococo BG, Petti MA, Viotti RJ. Clinical characteristics and outcome of 107 adult patients with chronic Chagas disease and parasitological cure criteria. Trans R Soc Trop Med Hyg. 2013;107(6):372–6. PubMed PMID: 23612468.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Viotti R, Vigliano C, Lococo B, Bertocchi G, Alvarez M, Laucella S, et al. Tratamiento antiparasitario en la enfermedad de Chagas. Enferm Emerg. 2008;10(Suppl 1):10–3.Google Scholar
  47. 47.
    Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144(10):724–34. PubMed PMID: 16702588.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, Ruiz Vera B, et al. Tratamiento de Chagas con benznidazol y ácido tióctico. Medicina (Buenos Aires). 2004;64(1):1–6.Google Scholar
  49. 49.
    Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas’ disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994;127(1):151–62. PubMed PMID: 8273735.PubMedCrossRefGoogle Scholar
  50. 50.
    Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. J Am Coll Cardiol. 2017;69(8):939–47. PubMed PMID: 28231946.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Sguassero Y, Cuesta CB, Roberts KN, Hicks E, Comande D, Ciapponi A, et al. Course of chronic Trypanosoma cruzi Infection after treatment based on parasitological and serological tests: a systematic review of follow-up studies. PLoS One. 2015;10(10):e0139363. PubMed PMID: 26436678. Pubmed Central PMCID: 4593559.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Carlier Y, Torrico F, Sosa-Estani S, Russomando G, Luquetti A, Freilij H, et al. Congenital Chagas disease: recommendations for diagnosis, treatment and control of newborns, siblings and pregnant women. PLoS Negl Trop Dis. 2011;5(10):e1250. PubMed PMID: 22039554. Pubmed Central PMCID: 3201907.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Coura JR, de Abreu LL, Willcox HP, Petana W. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas’ disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Estudo comparativo controloado com emprego de benznidazole, nifurtimox e placebo, na forma cronica da doenca de Chagas; em uma area de campo com transmissao interrompida. I. Avalicao preliminar. Rev Soc Bras Med Trop. 1997;30(2):139–44.PubMedCrossRefGoogle Scholar
  54. 54.
    Gallerano RR, Sosa RR. Estudio de intervención en la evolución natural de la enfermedad de Chagas. Evaluación del tratamiento antiparasitario específico. Estudio retrospectivo-prospectivo de terapéutica antiparasitaria. Rev Fac Cien Med Univ Nac Cordoba. 2000;57(2):135–62.PubMedGoogle Scholar
  55. 55.
    de Castro AM, Luquetti AO, Rassi A, Chiari E, Galvao LM. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res. 2006;99(4):379–83. PubMed PMID: 16570199.PubMedCrossRefGoogle Scholar
  56. 56.
    Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis. 2009;3(7):e488. PubMed PMID: 19582142. Pubmed Central PMCID: 2700957.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Molina I, Salvador F, Sanchez-Montalva A, Artaza MA, Moreno R, Perin L, et al. Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials. Antimicrob Agents Chemother. 2017;61(4):e01912–6. PubMed PMID: 28167552. Pubmed Central PMCID: 5365666.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Soy D, Aldasoro E, Guerrero L, Posada E, Serret N, Mejia T, et al. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother. 2015;59(6):3342–9. PubMed PMID: 25824212. Pubmed Central PMCID: 4432184.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373(14):1295–306. PubMed PMID: 26323937.PubMedCrossRefGoogle Scholar
  60. 60.
    Alvarez MG, Hernandez Y, Bertocchi G, Fernandez M, Lococo B, Ramirez JC, et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: a pilot short-term follow-up study with adult patients. Antimicrob Agents Chemother. 2016;60(2):833–7. PubMed PMID: 26596935. Pubmed Central PMCID: 4750658.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Morillo CA, Marin-Neto JA, Avezum A. Benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2016;374(2):189–90. PubMed PMID: 26760092.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Rassi A Jr, Marin Neto JA, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz. 2017;112(3):224–35.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, Holanda MT, Silvestre de Sousa A, Sangenis LHC, et al. Benznidazole treatment safety: the Medecins Sans Frontieres experience in a large cohort of Bolivian patients with Chagas’ disease. J Antimicrob Chemother. 2017;72(9):2596–601. PubMed PMID: 28645201.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2010;4(5):e720. PubMed PMID: 20520803. Pubmed Central PMCID: 2876135.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA. Investigations on the pharmacokinetics of nifurtimox-35 S in the rat and dog. Arzneimittelforschung. 1972;22(9):1617–24. PubMed PMID: 4630484.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Haberkorn A, Gonnert R. Animal experimental investigation into the activity of nifurtimox against Trypanosoma cruzi. Arzneimittelforschung. 1972;22(9):1570–82. PubMed PMID: 4630483.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Gonzalez-Martin G, Thambo S, Paulos C, Vasquez I, Paredes J. The pharmacokinetics of nifurtimox in chronic renal failure. Eur J Clin Pharmacol. 1992;42(6):671–3. PubMed PMID: 1623911.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Paulos C, Paredes J, Vasquez I, Kunze G, Gonzalez-Martin G. High-performance liquid chromatographic determination of nifurtimox in human serum. J Chromatogr. 1988;433:359–62. PubMed PMID: 3235567.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Paulos C, Paredes J, Vasquez I, Thambo S, Arancibia A, Gonzalez-Martin G. Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1989;27(9):454–7. PubMed PMID: 2807618.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Saulnier Sholler GL, Bergendahl GM, Brard L, Singh AP, Heath BW, Bingham PM, et al. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol. 2011;33(1):25–30. PubMed PMID: 21063221.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Medenwald H, Brandau K, Schlossmann K. Quantitative determination of nifurtimox in body fluids of rat, dog and man. Arzneimittel-Forschung. 1972;22(9):1613–7. PubMed PMID: 4678720.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Gonzalez-Martin G, Paulos C, Guevara A, Ponce G. Disposition of nifurtimox and metabolite activity against Trypanosoma cruzi using rat isolated perfused liver. J Pharm Pharmacol. 1994;46(5):356–9. PubMed PMID: 8083806.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Letelier ME, Izquierdo P, Godoy L, Lepe AM, Faundez M. Liver microsomal biotransformation of nitro-aryl drugs: mechanism for potential oxidative stress induction. J Appl Toxicol. 2004;24(6):519–25. PubMed PMID: 15558828.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Masana M, de Toranzo EG, Castro JA. Studies on nifurtimox nitroreductase activity in liver and other rat tissues. Arch Int Pharmacodynam Ther. 1984;270(1):4–10. PubMed PMID: 6497502.Google Scholar
  75. 75.
    Garcia-Bournissen F, Altcheh J, Panchaud A, Ito S. Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis. Arch Dis Child. 2010;95(3):224–8. PubMed PMID: 19948512.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Watson CP, Dogruel M, Mihoreanu L, Begley DJ, Weksler BB, Couraud PO, et al. The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 2012;1436:111–21. PubMed PMID: 22200378. Pubmed Central PMCID: 3281990.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Cancado JA, Salgado AA, Marra UD, Alvares JM, Machado JR. [Clinical therapeutic trial in chronic Chagas’ disease using nifurtimox in 3 schedules of long duration]. Ensaio terapeutico cl’inico na doenca de Chagas cronica com o nifurtimox em tres esquemas de dura coa prolongada. Rev Inst Med Trop Sao Paulo. 1975;17(2):111–27.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Freilij H, Altcheh J. Congenital Chagas’ disease: diagnostic and clinical aspects. Clin Infect Dis. 1995;21(3):551–5. PubMed PMID: 8527542.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Coura JR. [Current prospects of specific treatment of Chagas’ disease] Perspectivas actuales del tratamiento especifico de la enfermedad de Chaga. Bol Chil Parasitol. 1996;51(3–4):69–75. PubMed PMID: 9302778.PubMedGoogle Scholar
  80. 80.
    Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis. 2010;51(10):e69–75. PubMed PMID: 20932171.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Forsyth CJ, Hernandez S, Olmedo W, Abuhamidah A, Traina MI, Sanchez DR, et al. Safety profile of nifurtimox for treatment of Chagas disease in the United States. Clin Infect Dis. 2016;63(8):1056–62. PubMed PMID: 27432838. Pubmed Central PMCID: 5036918.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Alarcon de Noya B, Ruiz-Guevara R, Noya O, Castro J, Ossenkopp J, Diaz-Bello Z, et al. Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report. Expert Rev Anti-Infect Ther. 2017;15(3):319–25. PubMed PMID: 28132566.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Perez-Molina JA, Sojo-Dorado J, Norman F, Monge-Maillo B, Diaz-Menendez M, Albajar-Vinas P, et al. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop. 2013;127(2):101–4. PubMed PMID: 23583863.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Facundo Garcia-Bournissen
    • 1
    • 2
  1. 1.Servicio de Parasitología y Enfermedad de ChagasHospital de Niños “Ricardo Gutiérrez”Buenos AiresArgentina
  2. 2.Instituto Multidisciplinario de Investigación en Patologías Pediátricas (IMIPP-GCBA)Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)Buenos AiresArgentina

Personalised recommendations